| Literature DB >> 29291713 |
Satoshi Okamori1, Takanori Asakura1, Tomoyasu Nishimura2, Eiko Tamizu2, Makoto Ishii1, Mitsunori Yoshida3, Hanako Fukano3, Yuichiro Hayashi4, Masaki Fujita5, Yoshihiko Hoshino3, Tomoko Betsuyaku1, Naoki Hasegawa6.
Abstract
BACKGROUND: Presence of Mycobacterium fortuitum in respiratory tracts usually indicates mere colonization or transient infection, whereas true pulmonary infection occurs in patients with gastroesophageal disease. However, little is known about the diagnostic indications for true M. fortuitum pulmonary infection and the natural history of the disease. CASEEntities:
Keywords: Aspiration; Lipoid pneumonia; Mycobacterial infection; Nontuberculous mycobacteria (NTM); Rapidly growing mycobacteria (RGM)
Mesh:
Substances:
Year: 2018 PMID: 29291713 PMCID: PMC5748953 DOI: 10.1186/s12879-017-2892-9
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1a Chest imaging performed during the referral showed infiltrates in the right upper and left lower lung fields and bilateral middle fields. b Computed tomography images showed consolidations and nodular shadows in multiple lung lobes. c The esophagus was dilated with food residue (arrow)
Fig. 2Chest imaging performed during the observation. a At 6 months after the referral. New infiltrates appeared in the left middle field (white arrow). b At 14 months after the referral. The consolidation in the right upper field was deteriorated, and the infiltrates in the left middle field migrated toward the lower right (black arrows). c At 25 months after the referral. The infiltrations in the left lung field were improved without treatment. d At 28 months after the referral. New infiltrates appeared bilaterally (white arrowhead) e At 38 months after the referral. The patients developed apparent aspiration pneumonia, with chest radiograph showing bilateral consolidations. f At 5 years after treatment against M. fortuitum was started. Multiple pulmonary lesions improved
Fig. 3Photomicrographs of computed tomography-guided lung biopsy specimens showing foamy macrophages in the alveolar spaces (black arrows) and multinucleated giant cells (white arrow)
Fig. 4Photomicrographs of transbronchial lung biopsy specimens. a An epithelioid granuloma with necrosis. b Langhans giant cells (white arrow)
Clinical course of the treatment
| Treatment regimen | Start time | Duration | Note |
|---|---|---|---|
| RIF + EB + CLA + LVFX | 3 years before the referral | 1 year | |
| RIF + EB + CLA + INH | 8 months before the referral | 8 months | |
| MEPM → ABPC/SBT | 38 months after the referral | 2 weeks | Treatment for aspiration pneumonia |
| IPM/CS (for 2 weeks) + | 40 months after the referral | 5 years (continuing) | Improvement and no recurrence of migratory infiltrates |
Abbreviations: RIF rifampicin, EB ethambutol, CLA clarithromycin, LVFX levofloxacin; INH isoniazid, MEPM meropenem, ABPC/SBT ampicillin/sulbactum, IPM/CS, imipenem/cilastatin, AMK amikacin, MINO, minomycin
Fig. 5Randomly amplified polymorphic DNA polymerase chain reaction (RAPD-PCR) analysis with mycobacteria-specific primers as described in a previous study [23, 24]. Lane M, 100-bp DNA ladder size markers; lane T, type strain of M. fortuitum (ATCC 6841 strain); lanes F1 and F2, M. fortuitum clinical isolates from the cultures of other patients; lanes 1–7, M. fortuitum isolated from our patient (1–6, sputum; 7, intestinal fluid) RAPD-PCR patterns produced with primers OPA2, OPA18, and IS986FP are shown. Strains were determined to be identical when the same band patterns were observed with the three primers or one major band difference was observed in only one of the three primers
Drug sensitivity of the isolated strains
| Strain | Antibiotics | Isolated from | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLA | RIF | STFX | LVFX | EB | AMK | FRPM | DRPM | INH | MINO | IPM | TGC | ||
| 4 | >32 | 1 | ≦0.25 | 0.5 | 2 | 64 | 128 | 4 | ≦1 | >64 | 0.5 | sputum | |
| 64 | >32 | 0.25 | ≦0.25 | 0.5 | 8 | 2 | 32 | 4 | 4 | >64 | 0.5 | sputum (at referral) | |
| 64 | >32 | 0.125 | ≦0.25 | 0.5 | 4 | 4 | 32 | 8 | 16 | >64 | 0.5 | sputum (8 months after referral) | |
| 32 | >32 | 0.5 | ≦0.25 | 0.5 | 8 | 2 | 32 | 8 | 16 | >64 | 0.5 | sputum (14 months after referral, at the 2nd bronchoscopy) | |
| 128 | >32 | 0.25 | ≦0.25 | 0.5 | 4 | 2 | 32 | 4 | 8 | >64 | 0.5 | sputum (18 months after referral) | |
| 32 | >32 | 0.125 | ≦0.25 | 0.5 | 4 | 4 | 32 | 8 | 16 | >64 | 0.5 | sputum (35 months after referral) | |
| 32 | >32 | 0.125 | ≦0.25 | 0.5 | 4 | 4 | 32 | 8 | 16 | >64 | 0.5 | sputum (38 months after referral, at the 3rd bronchoscopy) | |
| 32 | >32 | 0.125 | ≦0.25 | 0.5 | 4 | 4 | 64 | 8 | 8 | >64 | 0.5 | intestinal fluid (38 months after referral) | |
The isolates were incubated with cation-adjusted Mueller-Hinton broth at 30 °C. Abbreviations: CLA clarithromycin, RIF rifampicin, STFX sitafloxacin, LVFX levofloxacin, EB ethambutol, AMK amikacin, FRPM faropenem, DRPM doripenem, INH, isoniazid, MINO minomycin, IPM imipenem, TGC tigecycline